×

Global Capecitabine Market Expected to Drop to US$ 1024 Mn by End of 2025

 3.0   Star Rating

 Published Date : 25 Nov 19   |   Views: 81   |  Industry : Life Science

Global Capecitabine Market Expected to Drop to US$ 1024 Mn by End of 2025

QYR Consulting has published a new report in the pharma & healthcare archive titled, “Capecitabine Market Report: Company Analysis, History and Future Overview, Global Sales Trends by 2025”. According to a study published in the report, the global Capecitabine market was valued at US$ 1047 Mn, in 2018 and is expected to drop to US$ 1024 by the end of 2025. The worldwide Capecitabine market is anticipated to register a drop of -0.3% CAGR over the projected duration of 2019 to 2025. Capecitabine is a chemotherapy drug, which is used in treatment for combating, preventing and reducing the progression of cancer cells in cancer patients. The drug is administered based on medical condition, body size, and response to treatment.

Segmental Analysis

High Usage of Capecitabine in the Treatment of Cancer to Foster Application Segment Growth

 

Based on the application, the market is bifurcated into colorectal cancer, breast cancer, and stomach cancer. Based on the product, the market is segmented into 150mg and 500mg. Due to higher usage of Capecitabine in various sub-segments of application segment such as breast cancer and others is expected to create a positive impact on the entire application segment. 

Global Capecitabine Market Expected to Drop to US$ 1024 Mn by End of 2025

North America

Global Capecitabine Market Expected to Drop to US$ 1024 Mn by End of 2025

Regional Analysis


Increasing Instances of Cancer in North America to Propel the Growth of Capecitabine Market

 

North America accounts for a significant share of the market due to increasing instances of cancer. Europe held a significant share of the market, which has recorded an increasing rate of deaths due to cancer. The Asia Pacific is a major tobacco consuming region and has a low rate of awareness regarding cancer, and an increasing rate of deaths due to cancer. The government in the region is facilitating awareness programs about symptoms and diagnosis of cancer and conducting screening drives, which is expected to drive the growth of the market. Due to poor health care facilities in Middle-East and Africa, the market is expected to witness significant growth.

Key Players


R&D Activities Offer New Scope to Manufacturers to Boost Sales

 

Teva, Roche, Hikma, Mylan, Cipla, Hengrui Medicine, Reliance Group, Heter, and Cipla are some of the major operating players of the global Capecitabine market. Increasing R&D activities related to Capecitabine are expected to offer new scope for the manufacturers.


Global Capecitabine Market Expected to Drop to US$ 1024 Mn by End of 2025

Global CAGR During 2019-2025


-0.3%

Market Dynamics


High Cost and Adverse Effects Expected to Hamper Market Growth

 

The high cost of the drug and adverse effects are expected to hamper the growth of the market. The market has a considerable presence of substitutes of Capecitabine such as leucovorin and raltitrexed, which is restraining the growth of the market. The government imposed rules and regulations regarding the safety and efficacy of the drug is likely to hinder the growth of the market.


For further information, check: https://www.qyrconsulting.com/reports/capecitabine-market


Ask a Question

Get in touch with us to find answers to all your business-related queries for fast results.

  Thank you for sharing your rating with us.